Requires invasive procedure |
Minimally invasive |
Unable to capture tumour heterogeneity |
Overcomes challenges of tumour heterogeneity |
Unable to assess temporal genomic changes |
Real time genomic monitoring and cancer evolution monitoring |
Very low risk of false positives (CHIP) |
Risk of false positives (CHIP) |
Risk of non-diagnostic sample |
Variable detection rate (dependant on stage, site of metastases, type of cancer) |
Technical consideration for tissue processing required (storage of tissue, cutting, histopathological review) |
Pre-analytical variable requirements (plasma storage, isolation, and processing) |
Larger DNA collection and input for broad sequencing panels (including WES/WGS) |
Variable DNA collection (possible limitations for WES/WGS) |